Company intelligence / Profile preview
Allozyne
Seattle, Washington, United States
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Allozyne's lead program AZ01 (pegylated recombinant human interferon beta) was in Phase 1 for relapsing-remitting multiple sclerosis. The company developed protein engineering platforms for site-specific incorporation of non-natural amino acids, enabling improved biologics and next-generation antibody-drug conjugates. Allozyne was acquired by MedImmune in 2014, and no recent clinical results have been reported since acquisition[1][5].
- Therapeutic areas
- OncologyGastroenterologyNeurologyImmunology
- Modalities
- Recombinant proteinAntibody-drug conjugateProtein
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
The Scripps Research Institute
Beyond the preview
Go deeper on Allozyne.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allozyne.